Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost more than 50% of its value in 2026 and more than 95% over the past five years, reflecting its unprofitable operations and highly uncertain outlook. The potential upside rests on eventual U.S. cannabis legalization—or even credible legislative discussions—which could trigger speculative buying similar to the rally in Canadian cannabis stocks ahead of Canada’s October 2018 legalization. Tilray’s expansion into U.S. beverage and alcohol assets may provide infrastructure for a future cannabis entry, but the article views the stock as appropriate only for investors with very high risk tolerance.

Analysis

TLRY is better viewed as a regulatory-duration option than an operating turnaround. Its U.S. beverage footprint may provide distribution knowledge, but it does not create a defensible right to sell THC products across state lines; federal reform would still require capital, licenses, and likely partnerships. The more probable near-term catalyst is administrative reform or congressional momentum, which can re-rate cannabis equities before any cash-flow impact but does not solve TLRY's dilution and profitability problem.

Competitive dynamics favor U.S. multi-state operators—GTBIF, TCNNF, CURLF and VRNOF—if reform improves banking, exchange listing access, or tax treatment. They already possess retail density, local brands, and state licenses; Canadian LPs such as TLRY, ACB, and WEED would likely receive the larger initial percentage move because of retail positioning and lower liquidity, but face weaker fundamental capture. This makes a Canadian-LP rally more vulnerable to reversal once investors differentiate legal optionality from executable U.S. EBITDA.

Over days to weeks, monitor federal scheduling/banking headlines and unusual volume in MSOS versus TLRY. A TLRY-only spike without confirmation from MSOS would signal a retail-led momentum move rather than a broad improvement in sector economics. Over 6-18 months, the thesis is falsified if TLRY cannot narrow adjusted EBITDA losses and fund operations without material share issuance; each equity raise raises the regulatory catalyst required merely to offset dilution.

Contrarian view: the market may overpay for the most recognizable Canadian proxy while underpricing MSOS beneficiaries of improved tax and capital-market access. Full legalization is not necessary for MSO earnings upside, whereas TLRY requires both policy change and successful market entry. The article provides no independently verifiable evidence that TLRY's U.S. assets translate into cannabis conversion economics, so no core long is justified on this signal alone.

Key Decisions for Investors

• No standalone TLRY long at current information set; treat it as an event-driven watchlist name. Consider only after a verified federal catalyst and confirmation that MSOS outperforms broad equities for 2-3 sessions on elevated volume.
• On a policy-driven cannabis rally, express relative value long MSOS / short TLRY over a 1-3 month horizon. MSOS offers greater exposure to existing U.S. operators; TLRY is more exposed to retail-chasing and future dilution. Exit if TLRY materially outperforms MSOS after reform details establish a credible Canadian-LP entry pathway.
• For tactical event exposure, prefer defined-risk TLRY call spreads rather than equity—for example 1-3 month out-of-the-money call spreads initiated only after a concrete scheduling, SAFE Banking, or legislative-calendar catalyst. Size as premium-at-risk; policy headlines can reverse intraday.
• Track TLRY quarterly cash burn, adjusted EBITDA trajectory, share count, and any capital raise. A worsening cash runway or share-count increase is a short/avoid signal even if cannabis-sector sentiment improves.
• Use ACB and WEED as sentiment comparables, not fundamental substitutes. A synchronized surge across TLRY/ACB/WEED that exceeds MSOS performance is an indicator to fade late-stage Canadian-LP momentum rather than add exposure.